Growth Metrics

Haemonetics (HAE) Equity Ratio (2016 - 2025)

Haemonetics (HAE) has 16 years of Equity Ratio data on record, last reported at 0.37 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 2.14% year-over-year to 0.37; the TTM value through Dec 2025 reached 0.37, up 2.14%, while the annual FY2025 figure was 0.33, 23.4% down from the prior year.
  • Equity Ratio reached 0.37 in Q4 2025 per HAE's latest filing, up from 0.35 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.44 in Q3 2023 and bottomed at 0.33 in Q1 2025.
  • Average Equity Ratio over 5 years is 0.39, with a median of 0.39 recorded in 2022.
  • Peak YoY movement for Equity Ratio: decreased 26.87% in 2022, then rose 13.68% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.39 in 2021, then rose by 6.56% to 0.41 in 2022, then increased by 3.76% to 0.43 in 2023, then dropped by 16.43% to 0.36 in 2024, then increased by 2.14% to 0.37 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.37 in Q4 2025, 0.35 in Q3 2025, and 0.36 in Q2 2025.